1-(2-氯乙氧基)-3-甲氧基苯 | 102877-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-氯乙氧基)-3-甲氧基苯
• 英文名称: 1-(2-chloroethoxy)-3-methoxybenzene
• 英文别名: 1-(2-chloro-ethoxy)-3-methoxy-benzene；1-(2-Chlor-aethoxy)-3-methoxy-benzol；O-Methyl-O'-(2-chlor-aethyl)-resorcin；2-(3-Methoxy-phenoxy)-aethylchlorid
• CAS: 102877-31-6
• 化学式: C₉H₁₁ClO₂
• 分子量: 186.638
• InChiKey: MZITZAORZBGNDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  去甲哌替啶 、 1-(2-氯乙氧基)-3-甲氧基苯 在 戊醇 、 sodium carbonate 作用下， 生成 1-[2-(3-methoxy-phenoxy)-ethyl]-4-phenyl-piperidine-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  622.一些新的哌替啶类似物。第三部分 1-芳氧基-烷基norpethidines，和类似的类似物

  摘要：

  DOI：

  10.1039/jr9580003065
• 作为产物：
  描述：

  2-(3-methoxyphenoxy)ethanol 在 五氯化磷 作用下， 生成 1-(2-氯乙氧基)-3-甲氧基苯
  参考文献：
  名称：

  255.取代酚的β-羟乙基醚及相关物质

  摘要：

  DOI：

  10.1039/jr9350001098

文献信息

• [EN] NEW 1-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF<br/>[FR] NOUVEAUX LIGANDS 1-ARYLPIPÉRAZINIQUES DE RÉCEPTEUR 5-HT7 ET UTILISATION DE CEUX-CI
  申请人：UNIV BARI

  公开号：WO2012159662A1

  公开（公告）日：2012-11-29

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.

  这项发明涉及一类新的化合物，能够以高亲和力和选择性抑制5-HT7受体。该发明还涉及将这类化合物用作药物，用于治疗和预防中枢神经系统与5-HT7受体相关的疾病。该发明还涉及同位素标记的化合物，用于体内诊断或成像5-HT7状况。
• NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF
  申请人：UNIVERSITA' DEGLI STUDI DI BARI ''ALDO MORO''

  公开号：US20140086834A1

  公开（公告）日：2014-03-27

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.

  该发明涉及一类新的化合物，能够高亲和力和选择性地抑制5-HT7受体。该发明还涉及将这类化合物用作药物，用于治疗和预防中枢神经系统与5-HT7受体相关的疾病。该发明还涉及同位素标记的化合物，用于体内诊断或成像5-HT7状况。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• I-arylpiperazinic ligands of 5-HT7 receptor and use thereof
  申请人：Leopoldo Marcello

  公开号：US09260400B2

  公开（公告）日：2016-02-16

  The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor and having the following formula IV: wherein W is O; K, L, M and Q is CH or nitrogen; R1 is hydrogen; R2 is hydrogen; and Ar is an aromatic ring with the following formula: wherein X, Y and Z is CH; and R3 is a five- or six-membered ring selected from the group consisting of:

  本发明涉及一种新的化合物类别，能够高亲和力和选择性地抑制5-HT7受体，并具有以下公式IV：其中W为O；K、L、M和Q为CH或氮；R1为氢；R2为氢；而Ar为具有以下公式的芳香环：其中X、Y和Z为CH；而R3为从以下组中选择的五元或六元环：
• QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1243582A1

  公开（公告）日：2002-09-25

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: wherein R1 and R2 represent hydrogen, alkyl or the like; R3, R4, R5, and R6 represent hydrogen, halogen, alkyl, alkoxy or the like; R11 and R12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R3, R4, R5 and R6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了可用于治疗由 PDGF 受体自身磷酸化介导的疾病的化合物，特别是可抑制新内膜形成肥厚的化合物。这些化合物是式 (I) 所代表的化合物或其药理学上可接受的盐或溶液： 其中 R1 和 R2 代表氢、烷基或类似物；R3、R4、R5 和 R6 代表氢、卤素、烷基、烷氧基或类似物；R11 和 R12 代表氢、烷基、烷基羰基或类似物；A 代表式(i)至(x)中的任意一种，但不包括 R3、R4、R5 和 R6 代表氢且 A 代表基团(v)（其中 u 为 0（零）且 R19 代表任选被卤素、烷基或烷氧基取代的苯基）的化合物。